Verastem (VSTM) stock tumbled 6.06% in pre-market trading on Tuesday, despite reporting better-than-expected Q3 2025 financial results. The biotechnology company's shares faced selling pressure as investors weighed the increased net loss against revenue gains.

Verastem reported Q3 net product revenue of $11.2 million, marking a successful product launch and significantly beating analyst estimates of $5.659 million. The company's adjusted earnings per share came in at $(0.54), surpassing the consensus estimate of $(0.64). However, the wider net loss of $98.5 million, compared to $24.0 million in the same period last year, appears to have overshadowed these positive aspects.

The increased net loss can be attributed to higher operating expenses, which reached $51.957 million for the quarter. Verastem noted that the rise in expenses was primarily due to increased drug substance and drug product costs, contract research organization costs, and investigator trial expenses. Despite the wider loss, the company maintains a positive outlook, expecting its cash runway to extend into the second half of 2026. Additionally, Verastem reported promising preliminary results for its VS-7375 trial in KRAS G12D mutant solid tumors, with plans to provide an interim safety and efficacy update in the first half of 2026. The pre-market decline suggests that investors may be focusing on the near-term financial challenges rather than the potential long-term prospects of the company's pipeline.